🚀 VC round data is live in beta, check it out!
Gensight Biologics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gensight Biologics and similar public comparables like Nanogroup, Quince Therapeutics, Advicenne, Poltreg and more.
Gensight Biologics Overview
About Gensight Biologics
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology, where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Founded
2012
HQ
Employees
12
Website
Sectors
Financials (LTM)
EV
$35M
Gensight Biologics Financials
Gensight Biologics reported last 12-month revenue of $2M and negative EBITDA of ($15M).
In the same LTM period, Gensight Biologics generated ($15M) in EBITDA losses and had net loss of ($15M).
Revenue (LTM)
Gensight Biologics P&L
In the most recent fiscal year, Gensight Biologics reported revenue of $751K and EBITDA of ($10M).
Gensight Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $751K | XXX | XXX | XXX |
| EBITDA | ($15M) | XXX | ($10M) | XXX | XXX | XXX |
| EBITDA Margin | (593%) | XXX | (1363%) | XXX | XXX | XXX |
| EBIT Margin | (642%) | XXX | (1734%) | XXX | XXX | XXX |
| Net Profit | ($15M) | XXX | ($14M) | XXX | XXX | XXX |
| Net Margin | (626%) | XXX | (1846%) | XXX | XXX | XXX |
| Net Debt | — | — | $12M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gensight Biologics Stock Performance
Gensight Biologics has current market cap of $23M, and enterprise value of $35M.
Market Cap Evolution
Gensight Biologics' stock price is $0.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35M | $23M | -1.8% | XXX | XXX | XXX | $-0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGensight Biologics Valuation Multiples
Gensight Biologics trades at 14.2x EV/Revenue multiple, and (2.4x) EV/EBITDA.
EV / Revenue (LTM)
Gensight Biologics Financial Valuation Multiples
As of April 18, 2026, Gensight Biologics has market cap of $23M and EV of $35M.
Equity research analysts estimate Gensight Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gensight Biologics has a P/E ratio of (1.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $23M | XXX | $23M | XXX | XXX | XXX |
| EV (current) | $35M | XXX | $35M | XXX | XXX | XXX |
| EV/Revenue | 14.2x | XXX | 46.4x | XXX | XXX | XXX |
| EV/EBITDA | (2.4x) | XXX | (3.4x) | XXX | XXX | XXX |
| EV/EBIT | (2.2x) | XXX | (2.7x) | XXX | XXX | XXX |
| P/E | (1.5x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | (3.1x) | XXX | (3.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gensight Biologics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gensight Biologics Margins & Growth Rates
Gensight Biologics' revenue in the last 12 month grew by 680%.
Gensight Biologics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.1M for the same period.
Gensight Biologics' rule of 40 is 551051% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gensight Biologics' rule of X is 1378090% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Gensight Biologics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 680% | XXX | 765% | XXX | XXX | XXX |
| EBITDA Margin | (593%) | XXX | (1363%) | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 96% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 551051% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 1378090% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 399% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1010% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1734% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gensight Biologics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gensight Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanogroup | XXX | XXX | XXX | XXX | XXX | XXX |
| Quince Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Advicenne | XXX | XXX | XXX | XXX | XXX | XXX |
| Poltreg | XXX | XXX | XXX | XXX | XXX | XXX |
| Arterra Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gensight Biologics M&A Activity
Gensight Biologics acquired XXX companies to date.
Last acquisition by Gensight Biologics was on XXXXXXXX, XXXXX. Gensight Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gensight Biologics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGensight Biologics Investment Activity
Gensight Biologics invested in XXX companies to date.
Gensight Biologics made its latest investment on XXXXXXXX, XXXXX. Gensight Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gensight Biologics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gensight Biologics
| When was Gensight Biologics founded? | Gensight Biologics was founded in 2012. |
| Where is Gensight Biologics headquartered? | Gensight Biologics is headquartered in France. |
| How many employees does Gensight Biologics have? | As of today, Gensight Biologics has over 12 employees. |
| Is Gensight Biologics publicly listed? | Yes, Gensight Biologics is a public company listed on Euronext Paris. |
| What is the stock symbol of Gensight Biologics? | Gensight Biologics trades under SIGHT ticker. |
| When did Gensight Biologics go public? | Gensight Biologics went public in 2016. |
| Who are competitors of Gensight Biologics? | Gensight Biologics main competitors are Nanogroup, Quince Therapeutics, Advicenne, Poltreg. |
| What is the current market cap of Gensight Biologics? | Gensight Biologics' current market cap is $23M. |
| What is the current revenue of Gensight Biologics? | Gensight Biologics' last 12 months revenue is $2M. |
| What is the current revenue growth of Gensight Biologics? | Gensight Biologics revenue growth (NTM/LTM) is 680%. |
| What is the current EV/Revenue multiple of Gensight Biologics? | Current revenue multiple of Gensight Biologics is 14.2x. |
| Is Gensight Biologics profitable? | No, Gensight Biologics is not profitable. |
| What is the current EBITDA of Gensight Biologics? | Gensight Biologics has negative EBITDA and is not profitable. |
| What is Gensight Biologics' EBITDA margin? | Gensight Biologics' last 12 months EBITDA margin is (593%). |
| What is the current EV/EBITDA multiple of Gensight Biologics? | Current EBITDA multiple of Gensight Biologics is (2.4x). |
| What is the current FCF of Gensight Biologics? | Gensight Biologics' last 12 months FCF is ($11M). |
| What is Gensight Biologics' FCF margin? | Gensight Biologics' last 12 months FCF margin is (457%). |
| What is the current EV/FCF multiple of Gensight Biologics? | Current FCF multiple of Gensight Biologics is (3.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.